Drug Discovery · New York, NY · Founded 2019 · Privately Held (backing)
Developer of targeted therapy drugs designed for the treatment of hematologic cancers. Ajax Therapeutics is based in New York, NY and was founded in 2019. Its last known valuation is $193 million. It has raised $143 million across 3 recorded rounds; the latest was a $95 million Series C in May 2024.
Last price · $/share
—
Implied valuation
$192.5M
Total raised
$143.0M
Last round
Later Stage VC (Series C)
May 2024
Cap table — not yet on record
Ajax Therapeutics's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of Ajax Therapeutics with a free account
·The complete investor list: 11 names
·Watch Ajax Therapeutics: the Monday email on marks, rounds and moves
Where does Ajax Therapeutics's cap table come from?
Share classes are assembled from certificates of incorporation, priced-round filings, and disclosures across Ajax Therapeutics's 3 recorded funding rounds.
